$RGBP dCellVax Breast Cancer – dCellVax - IND
Post# of 10454
![Avatar](/images/ProfileImages/754971288_289_stock market picture.jpg)
Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
10 advanced breast cancer patients
Efficacy endpoints at 6 and 12 months
Establishment of safety will allow for rapid expansion of patient numbers
Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program
![1468559839.png](http://www.regenbiopharmainc.com/uploads/8/7/0/8/8708811/1468559839.png)
http://www.regenbiopharmainc.com/product-pipeline.html
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)